Vigil Neuroscience (NASDAQ:VIGL) Price Target Raised to $23.00

Vigil Neuroscience (NASDAQ:VIGL) had its price objective lifted by equities researchers at Wedbush from $22.00 to $23.00 in a research note issued to investors on Friday, Benzinga reports. The brokerage presently has an “outperform” rating on the stock. Wedbush’s price objective would suggest a potential upside of 452.88% from the stock’s previous close.

Several other analysts also recently weighed in on VIGL. HC Wainwright reiterated a “buy” rating and set a $24.00 price target on shares of Vigil Neuroscience in a research note on Friday. JMP Securities reissued a “market outperform” rating and issued a $23.00 price objective on shares of Vigil Neuroscience in a report on Thursday, April 18th.

Vigil Neuroscience Price Performance

NASDAQ:VIGL opened at $4.16 on Friday. The firm has a market cap of $156.33 million, a PE ratio of -2.11 and a beta of 1.94. Vigil Neuroscience has a 1-year low of $2.47 and a 1-year high of $10.22. The company has a 50-day moving average of $3.49 and a 200 day moving average of $3.31.

Vigil Neuroscience (NASDAQ:VIGL) last released its earnings results on Tuesday, May 7th. The company reported ($0.50) EPS for the quarter, topping analysts’ consensus estimates of ($0.60) by $0.10. Sell-side analysts anticipate that Vigil Neuroscience will post -2.09 EPS for the current fiscal year.

Institutional Trading of Vigil Neuroscience

Several institutional investors have recently bought and sold shares of the business. PEAK6 Investments LLC boosted its holdings in Vigil Neuroscience by 66.0% in the 3rd quarter. PEAK6 Investments LLC now owns 23,796 shares of the company’s stock worth $128,000 after buying an additional 9,459 shares during the last quarter. Strs Ohio acquired a new stake in Vigil Neuroscience during the fourth quarter worth about $27,000. Finally, Vanguard Group Inc. increased its position in Vigil Neuroscience by 11.9% during the first quarter. Vanguard Group Inc. now owns 894,473 shares of the company’s stock worth $3,050,000 after purchasing an additional 95,276 shares during the last quarter. 83.64% of the stock is owned by institutional investors and hedge funds.

Vigil Neuroscience Company Profile

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.